Found 2 clinical trials
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …
- 0 views
- 19 Feb, 2024
- 5 locations
Evaluation of the Satisfaction of Patients Coming "on Foot" in the Operating Room
For more than a year now, multimodal approaches such as early rehabilitation have been undertaken, including morning admission with an innovative principle of "3D" patient (standing, dignified, relaxed) no premedication, wearing glasses and wigs, Drinking on the morning of the intervention (2H before admission), Walking to the block on foot …
- 0 views
- 19 Feb, 2024
- 5 locations